18 Panel Drug Screen with ADLTX, EtG & Kratom

18 Panel Drug Screen with ADLTX, EtG and Kratom

The Serenity 18 Panel Drug Screen with ADLTX combines urine collection, preliminary drug screening and specimen-validity indicators in one integrated 120 mL cup.

Its listed configuration includes dedicated kratom, fentanyl, EtG, ketamine and tramadol assays alongside commonly requested drug-screening panels.

A distinguishing feature of this cup is its ADLTX component, which evaluates pH, specific gravity and creatinine.

These indicators provide information about selected characteristics of the urine specimen and are interpreted separately from the drug-screening results.

The configuration lists 17 drug-screening assays plus three specimen-validity indicators. The drug panels address screening targets, while the ADLTX indicators help personnel evaluate whether specimen characteristics require additional review.

For eligible forensic programs, this format brings collection and screening together while supporting a consistent process for labeling, result documentation and follow-up testing.

Buyers can compare the available 18 panel drug test cups to select the required combination of drug panels and specimen-validity features.

18 panel drug test list and Cutoff Levels

The listed drug-screening configuration includes the following assays and cutoff levels:

This list contains 17 drug-screening assays. The three ADLTX indicators below evaluate specimen characteristics separately.

Cutoff levels are screening thresholds. They do not measure dosage, establish impairment or determine the exact time of exposure. Follow the manufacturer’s instructions supplied with the device for interpretation and confirmation requirements.

ADLTX Specimen-Validity Checks

The ADLTX component evaluates three characteristics of the urine specimen:

Read each indicator using the reference chart and timing instructions supplied for the exact device. The drug-panel result window should not be assumed to apply to the ADLTX indicators.

An unusual indicator result may require further specimen review under the testing program’s procedures. It does not independently prove intentional tampering, identify every possible adulterant or replace laboratory specimen-validity testing.

Likewise, indicators within the manufacturer’s expected ranges do not establish that every possible specimen problem has been excluded.

For additional explanation, review our guide to adulterants and specimen-validity checks in drug testing.

Reading Adulterants test

How to Use the 18 Panel Drug Screen

Follow the manufacturer’s instructions supplied with the exact device. The following steps provide a general overview of collection and screening.

1. Prepare the device: Confirm the SKU, configuration, package condition and printed expiration date. Check that storage conditions meet the manufacturer’s requirements.
2. Identify the specimen: Follow your organization’s procedures for donor identification, specimen labeling and collection documentation.
3. Collect the urine: Collect directly into the cup using the volume specified in the product insert. The 120 mL cup capacity is not the required collection volume.
4. Secure the cup and complete collection checks: Close the lid as directed and follow the applicable specimen-temperature and handling procedures.
5. Read the ADLTX indicators: Compare pH, specific gravity and creatinine indicators with the supplied reference chart at their specified reading times.
6. Read and record the drug panels: Interpret the Control and Test lines within the manufacturer’s drug-result reading window. Document drug results and validity findings separately.

Use a timer and follow the instructions for each component. For an illustrated explanation of drug-panel result patterns, review our guide to reading a drug test cup.

How to Read the Screening Results

Interpret every drug assay separately and within the manufacturer’s specified reading window.

Preliminary negative: A Control line and a Test line appear for the corresponding assay. Evaluate faint Test lines according to the product insert. Line darkness should not be used to estimate drug concentration.

Preliminary non-negative: A Control line appears without a Test line for the corresponding assay. Arrange appropriate laboratory confirmation before treating the screening finding as definitive.

Invalid: The required Control line does not appear. Do not report the affected assay as negative or non-negative. Follow the manufacturer’s troubleshooting instructions and repeat testing with a new device as directed.

ADLTX findings: Interpret these indicators using their reference chart. They are separate from the Control and Test line interpretation used for the drug-screening assays.

Who Uses This Forensic Screening Configuration?

This 18 panel drug test with adulterants configuration is offered for eligible forensic applications, including:

• Law enforcement testing programs.
• Court-related forensic screening.
• Probation and parole programs.
• Correctional and detention facilities.
• Laboratories supporting authorized forensic testing.

Purchasing teams should confirm that the product’s labeled intended use, drug configuration and specimen-validity features match their organization’s requirements.

Collection personnel need the current product insert and the procedures governing specimen handling, result review and laboratory confirmation. Read our explanation of Forensic Use Only drug tests for additional information.

Detection Windows and Test Limitations

A screening cutoff does not establish a fixed detection window. Results can vary with the substance, timing and pattern of exposure, specimen concentration, assay cutoff and testing method.

A negative result does not exclude every possible exposure. A substance may be below the screening threshold, outside the assay’s detection capability or absent from the selected configuration.

Urine screening cannot determine impairment, dosage or the exact time of use. Unexpected findings and results affecting significant decisions require appropriate evaluation and confirmation. ARUP Consult’s drug testing guidance explains these limitations and the role of definitive testing.

Specimen-validity indicators provide additional information about the sample. They do not remove the limitations of preliminary drug screening.

Bulk 18 panel drug screen cup with ADLTX

DrugTestingCup.com offers quantity pricing for this configuration. Buyers can select the available purchasing options on this page or request assistance with larger orders.

For repeat purchases, identify the product by SKU SM-CDOA-9185AD3FUO and confirm that the required configuration includes the listed specialty assays and all three ADLTX indicators.

Free shipping is available on qualifying orders of 100 or more cups, with same-day shipping on qualifying orders placed before 3 PM EST.

For purchasing guidance, review our bulk drug test cup buying guide. Organizations arranging larger orders can contact DrugTestingCup.com for assistance.

Frequently Asked Questions

What does this 18 panel drug screen test for?

The listed drug-screening configuration includes AMP, BAR, BUP, BZO, COC, MDMA, MET, MTD, OPI, OXY, PCP, THC, TRA, FEN, EtG, KRA and KET. Separate ADLTX indicators evaluate pH, specific gravity and creatinine.

What does ADLTX mean on this cup?

ADLTX identifies the specimen-validity indicators. This configuration checks pH, specific gravity and creatinine separately from the drug-screening assays.

Does an unusual ADLTX result prove that a specimen was altered?

No. An unusual indicator result identifies a specimen characteristic that needs further review. It does not independently establish intentional tampering, identify every possible adulterant or replace laboratory specimen-validity testing.

Does this cup include kratom, fentanyl, EtG and ketamine?

Yes. The listed configuration includes dedicated KRA, FEN, EtG and KET screening panels, together with a separate tramadol assay and additional drug-screening panels.

How should the ADLTX indicators be read?

Compare each indicator with the reference chart supplied for the exact device, at the time specified by the manufacturer. Follow the instructions for the validity indicators and drug panels separately, and record the findings separately.

Is this 18 panel drug screen CLIA waived?

This product is offered as a Forensic Use Only configuration. Buyers requiring CLIA-waived testing should select a device with documentation supporting that status and their intended use.

What should happen after a non-negative drug-screening result?

Follow the testing program’s specimen-handling and result-review procedures, and obtain appropriate laboratory confirmation before treating the preliminary screening finding as definitive.

Can I order this ADLTX drug screen in bulk?

Yes. Quantity pricing is available through the product’s purchasing options. Use SKU SM-CDOA-9185AD3FUO when requesting assistance with bulk or repeat orders.